Abbisko Cayman Limited (HK:2256) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Abbisko Cayman Limited has announced the initiation of a Phase II clinical trial for its oral drugs ABSK061 and ABSK043, aimed at treating metastatic or unresectable solid tumors with FGFR2/3 alterations. These drugs have shown promising anti-tumor activity and a favorable safety profile in previous studies, making this trial a significant development for potential cancer treatments. Investors are advised to be cautious as the drugs are still under clinical evaluation.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.